ANN ARBOR, Mich. University of Michigan scientists report highly encouraging evidence that a super-fine oil-and-water emulsion, already shown to kill many other microbes, may be able to quell the ravaging, often drug-resistant infections that cause nearly all cystic fibrosis deaths.
Cystic fibrosis is an inherited chronic lung disease that affects 30,000 children and adults in the United States. Patients have mucus-clogged lungs that leave them vulnerable to repeated, ever more serious respiratory infections.
"A key finding in the study is that we have a product that shows very good activity against a variety of bacteria that are very resistant to all known antibiotics. These really are superbugs," says John J. LiPuma, M.D., first and corresponding author of the study in the journal Antimicrobial Agents and Chemotherapy.
The research is a collaboration between LiPuma, professor of pediatrics at the U-M Medical School, and James R. Baker Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences at U-M and the study's senior author. Nanoemulsions developed at Baker's institute consist of soybean oil, water, alcohol and surfactants forced by high-stress mechanical extrusion into droplets less than 400 nanometers in size.
These emulsions have already proved to be non-toxic, potent killers of bacteria such as Streptococcus pneumoniae, H. influenzae and gonorrhea, of viruses such as herpes simplex and influenza A, and of several fungi. Nanoemulsion treatments for cold sores and toenail fungus are in Phase 3 clinical trials.
"We have a product that looks like it could be safely administered to the lungs of people with cystic fibrosis," LiPuma says. If future trials show that patients can tolerate effective doses of the nanoemulsion, he adds, "This could be a major breakthrough in the treatment of cystic fibrosis."
The novel physical mode of action -- the nan
|Contact: Anne Rueter|
University of Michigan Health System